
Humana (HUM) Stock
Major Medicare insurer focused on senior care. Here's the price, business snapshot, and what's worth knowing about Humana in November 2026.
Humana Inc (HUM) is a major US health insurance and services company, best known for its large Medicare Advantage business alongside commercial and Medicaid plans. With a market cap around $35.5bn, Humana generates revenues from premiums, care-management services and health-services initiatives that aim to lower costs and improve outcomes. Investors often watch Humana for its exposure to the growing Medicare Advantage market and its push into value-based care, primary-care partnerships and home health services, which can offer structural growth if executed well. Key considerations include reimbursement policy, regulatory oversight, medical-cost trends and membership retention. The stock can be sensitive to election-driven healthcare policy and short-term claims volatility. This summary is educational and not personalised investment advice; returns are not guaranteed and the value of investments can fall as well as rise. Consider your goals, risk tolerance and seek independent advice before investing.
Why It’s Moving

Humana Hits 52-Week High Amid Debt Restructuring and Regulatory Scrutiny
- The company announced final results for cash tender offers on several senior notes due between 2029 and 2032, signaling active balance sheet management.
- Humana is launching its national Gold Card program on December 1 to reduce prior authorization requirements and streamline care access for patients.
- Shares retreated roughly 4% amid broader regulatory scrutiny affecting major healthcare giants, despite hitting a 52-week high earlier in the week.

Humana Hits 52-Week High Amid Debt Restructuring and Regulatory Scrutiny
- The company announced final results for cash tender offers on several senior notes due between 2029 and 2032, signaling active balance sheet management.
- Humana is launching its national Gold Card program on December 1 to reduce prior authorization requirements and streamline care access for patients.
- Shares retreated roughly 4% amid broader regulatory scrutiny affecting major healthcare giants, despite hitting a 52-week high earlier in the week.
Six-Month Growth Performance
When is the next earnings date for Humana (HUM)?
Humana has not yet announced a confirmed date for its next earnings report. Based on the company's historical reporting pattern, which typically follows a quarterly cadence of approximately three months after the previous release, the next report is expected in February 2027. This upcoming disclosure will cover financial results for the fourth quarter of fiscal year 2026. Investors should monitor official announcements for the precise scheduling details as they become available.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Humana's stock with a target price of $428.38, indicating growth potential.
Financial Health
Humana is performing well with strong revenue and cash flow, indicating solid financial stability.
Dividend
Humana's low dividend yield of 0.8% indicates limited income from dividends. If you invested $1000 you would be paid $8 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Medicare Advantage Focus
Humana’s scale in Medicare Advantage can be a structural growth engine, though outcomes depend on policy and medical-cost trends.
Care-Delivery Push
Investors may watch its moves into value-based care and home health since these can improve margins over time, but execution risk remains.
Regulatory Sensitivity
Policy and reimbursement changes materially affect profits and membership; consider regulatory risk alongside growth opportunities.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.